News

Press Releases

December 30, 2022
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous […]

Read more
November 7, 2022
OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022

30% ORR and 90% DCR in evaluable patients were achieved in the dose escalation portion of the study in metastatic […]

Read more
April 26, 2022
Oncoc4 Announces Fast Track Designation Granted By The U.S. FDA For ONC-392 Monotherapy In PD(L)1-Resistant NSCLC

A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway April 25, 2022, Rockville, Maryland — OncoC4, Inc., […]

Read more
April 1, 2022
Dr. Yang Liu Acknowledged as Top 20 Dynamic CEOs of 2022

ROCKVILLE, Md., Mar. 31, 2022 – The CEO Publication, a unique digital platform featuring the industry experts who have created […]

Read more
March 15, 2022
OncoC4 Recognized as a Top 10 Immunotherapy Solutions Providers

ROCKVILLE, Md., Mar. 15, 2022 – OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the “Top 10 Immunotherapy […]

Read more
Scroll to Top